More about

Empagliflozin

News
November 07, 2022
3 min read
Save

‘Clear’ reduction in CV, renal outcomes with SGLT2 inhibitors across all high-risk groups

‘Clear’ reduction in CV, renal outcomes with SGLT2 inhibitors across all high-risk groups

CHICAGO — A meta-analysis of 13 large SGLT2 inhibitor trials, including the recently published EMPA-KIDNEY trial, indicates that the drug class reduces CV and renal outcomes across all high-risk groups, with and without type 2 diabetes.

News
November 05, 2022
2 min read
Save

Empagliflozin lowers kidney disease progression, cardiovascular death in patients with CKD

Empagliflozin lowers kidney disease progression, cardiovascular death in patients with CKD

ORLANDO —Empagliflozin reduced kidney disease progression and cardiovascular death in patients with chronic kidney disease, according to data presented at ASN Kidney Week.

News
September 29, 2022
2 min read
Save

Empagliflozin HF benefits consistent across albumin levels: EMPEROR-Pooled

Empagliflozin HF benefits consistent across albumin levels: EMPEROR-Pooled

In adults with HF, empagliflozin was associated with a reduction in new macroalbuminuria in patients with macroalbuminuria at baseline compared with placebo.

News
June 17, 2022
7 min read
Save

A new horizon for guideline-directed medical therapy in HFpEF

A new horizon for guideline-directed medical therapy in HFpEF

Approximately 52% of patients with HF are categorized as those with a preserved ejection fraction. Hospitalizations in this patient population are continuing to increase.

News
June 14, 2022
2 min read
Save

Empagliflozin lowers risk for kidney stones in type 2 diabetes

Empagliflozin lowers risk for kidney stones in type 2 diabetes

ATLANTA — Use of empagliflozin was associated with a nearly 40% reduced risk for nephrolithiasis among people with type 2 diabetes, according to data presented at ENDO 2022.

News
June 03, 2022
2 min read
Save

ADA Standards of Care update reflects new data on CV, kidney disease in type 2 diabetes

ADA Standards of Care update reflects new data on CV, kidney disease in type 2 diabetes

The American Diabetes Association announced updates to its 2022 Standards of Medical Care in Diabetes to reflect new data on cardiovascular outcomes with diabetes and kidney disease and use of SGLT2 inhibitors.

News
April 07, 2022
3 min read
Save

Empagliflozin benefits acute HF regardless of baseline impairment: EMPULSE

Empagliflozin benefits acute HF regardless of baseline impairment: EMPULSE

WASHINGTON — Patients with acute HF assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo, with benefit seen as early as 15 days, data show.

News
April 05, 2022
2 min read
Save

Addition of empagliflozin improves daytime glucose in type 1 diabetes

Addition of empagliflozin improves daytime glucose in type 1 diabetes

Empagliflozin added to automated insulin delivery or predictive low-glucose suspend systems significantly benefited daytime glucose levels for people with type 1 diabetes, with no extra hypoglycemia risk, according to new data.

News
March 21, 2022
3 min read
Save

Mineralocorticoid receptor antagonist use does not affect empagliflozin benefit in HFpEF

Mineralocorticoid receptor antagonist use does not affect empagliflozin benefit in HFpEF

The benefit of the SGLT2 inhibitor empagliflozin in patients with HF with preserved ejection fraction did not differ between those who did or did not receive mineralocorticoid receptor antagonists, researchers reported.

News
March 17, 2022
1 min read
Save

Jardiance phase 3 trial shows efficacy in patients with CKD, trial will stop early

Jardiance phase 3 trial shows efficacy in patients with CKD, trial will stop early

The EMPA-Kidney trial will stop early due to evidence of Jardiance’s positive efficacy among patients with chronic kidney disease, according to a press release.

View more